ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LLAI Lunglife Ai Inc

28.00
-2.00 (-6.67%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lunglife Ai Inc LSE:LLAI London Ordinary Share ORD USD0.0001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -6.67% 28.00 29.00 31.00 30.00 30.00 30.00 10,000 16:35:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

LungLife AI, INC Publication of Annual Report & Notice of AGM (6835V)

06/04/2023 3:50pm

UK Regulatory


Lunglife Ai (LSE:LLAI)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Lunglife Ai Charts.

TIDMLLAI

RNS Number : 6835V

LungLife AI, INC

06 April 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company's website and have been posted to those shareholders who have opted out of electronic communications .

The documents are available here: https://investors.lunglifeai.com/

The Company's AGM will be held at 3:00 P.M. (BST) on 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. The Company will announce details of how to listen to the meeting remotely and any other significant changes to the meeting arrangements via RNS and on LungLife's website at https://investors.lunglifeai.com/

Shareholders are strongly encouraged to vote by proxy, whether or not they plan to attend the Company's AGM in person. Shareholders may register their votes on the resolutions of the AGM by completing and returning the Form of Proxy that accompanies the Notice of AGM in accordance with the instructions printed on the Form of Proxy.

Where shareholders hold Common Shares by way of dematerialised depository interests representing underlying Common Shares ("Depository Interests"), they can vote through the CREST system or by returning a Form of Direction to the Company's agent, Link Group. Further instructions are set out in the Notes to the Notice of AGM.

The resolutions to be proposed at the AGM are summarised in the Notice of AGM.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable possible after the AGM.

For further information please contact:

 
LungLife AI, Inc.                                                         www.lunglifeai.com 
Paul Pagano, CEO                                                             Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                Tel: +44 (0)20 7597 5970 
 & J oint Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
  Goodbody (Joint Broker)                               Tel: +44 (0) 20 3841 6202 / +353 (1) 
  Tom Nicholson / Stephen Kane                                                      667 0420 
 
Walbrook PR Limited                    Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Stephanie Cuthbert / Alice Woodings                     Mob: 07980 541 893 / 07407 804 654 / 
 / Phillip Marriage                                                            07867 984 082 
 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAIFMITMTIMBPJ

(END) Dow Jones Newswires

April 06, 2023 10:50 ET (14:50 GMT)

1 Year Lunglife Ai Chart

1 Year Lunglife Ai Chart

1 Month Lunglife Ai Chart

1 Month Lunglife Ai Chart

Your Recent History

Delayed Upgrade Clock